Skip to main content

Rheumatoid Arthritis

      RT @RichardPAConway: @MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients
      3 years 1 month ago
      @MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw
      RT @AkhilSoodMD: Abstr 0579
      Kim & Colleagues examined predictors of Tx change among RA patients w/ TNFi as 1st line
      3 years 1 month ago
      Abstr 0579 Kim & Colleagues examined predictors of Tx change among RA patients w/ TNFi as 1st line biologic agent - Females & GC use more likely to switch agent - Vitamin D use & hx of other immune-mediated diseases (eg. Psoriasis, IBD) less likely to switch #ACR21 @RheumNow https://t.co/FM5mSWmSNA
      The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a…
      Lung Now: Drs. Pope and Sparks
      RT @ericdeinmd: #ACR21 Abs#0825
      Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ)
      ⭐️Superiority f
      3 years 1 month ago
      #ACR21 Abs#0825 Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ) ⭐️Superiority for ABA+MTX and CZP+MTX vs. to csDMARD+GC, not in TCZ+MTX ⭐️ Radiographic progression low in all ▶️ Short study w very aggressive 1st line combo Rx https://t.co/TJPZkqmN8z @Rheumnow
      RT @ericdeinmd: #ACR21 Abs#0828. SELECT-COMPARE UPA vs ADA for RA at 3 yrs
      ⭐️More pts stay on UPA vs ADA (47 vs 36%)
      3 years 1 month ago
      #ACR21 Abs#0828. SELECT-COMPARE UPA vs ADA for RA at 3 yrs ⭐️More pts stay on UPA vs ADA (47 vs 36%) ⭐️Adverse drug events similar between groups. UPA has ⬆️ zoster, lymphopenia, hepatic and CPK elevations https://t.co/eLCytSX7Gz @Rheumnow https://t.co/i8NjSgImVq
      RT @AurelieRheumo: 🩸 Hb levels markers of RA activity and structural progression? Boston BRASS registry: 1500+ patien
      3 years 1 month ago
      🩸 Hb levels markers of RA activity and structural progression? Boston BRASS registry: 1500+ patients. Low hb at headline associated w/ MTX TNFi and ⬆️ increase in TSS. Not that surprising provided low Hb is a marker of systemic inflammation. #Abtr0786 #ACR21 @Rheumnow https://t.co/eQLGxsANkk
      RT @KDAO2011: Can RA be cured?
      Dr. Thomas' proof of concept RA immunotherapy study: DEN-181 is a liposome immunotherapy
      3 years 1 month ago
      Can RA be cured? Dr. Thomas' proof of concept RA immunotherapy study: DEN-181 is a liposome immunotherapy given by SQ injx; it's presented by LN-DCs causing: CTL exhaustion while controlling autoreactive CD4+ T cells #ACRbest @rheumnow #ACR21 Abst#0967should have been a plenary! https://t.co/6ZzDgavafS
      RT @DrMiniDey: Does #RA treatment affect low Hb levels? Is there a relationship between Hb and radiographic progression?
      3 years 1 month ago
      Does #RA treatment affect low Hb levels? Is there a relationship between Hb and radiographic progression? #ACR21 Abs#0787 👉🏼Sustained improvements in Hb when treated with bio/non-bio DMARDs 👉🏼Low Hb assoc with incr radiographic progression @RheumNow https://t.co/DWgoiqYfAt https://t.co/aSRCT2vGjW
      ×